Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Rationale: In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI. However, pneumonia incidence was higher in the inhale...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Am Thorac Soc
Main Authors: Dransfield, Mark T., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, LaFon, David, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert A., Lange, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: American Thoracic Society 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8086537/
https://ncbi.nlm.nih.gov/pubmed/33108212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.202002-096OC
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados